Indian pharmaceutical company Strides Arcolab has entered into a licensing agreement with US-based Gilead Sciences to manufacture and distribute latter's low-cost HIV drug, Tenofovir Alafenamide (TAF), in developing countries.
In a BSE filing, Strides Arcolab said, "It has entered into a licensing agreement with Gilead Sciences, Inc under which Gilead has extended non-exclusive rights to Strides to manufacture and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs."
AdvertisementStrides said that the license being granted to it extends to 112 countries.
"Strides will receive technology transfer from Gilead, enabling Strides to manufacture low cost versions of TAF for developing countries," the company stated.
TAF is an investigational product in the US and have not yet been determined safe and efficacious in humans.